Format

Send to

Choose Destination
Trends Endocrinol Metab. 2017 Aug;28(8):545-560. doi: 10.1016/j.tem.2017.05.004. Epub 2017 Jun 21.

AMPK as a Therapeutic Target for Treating Metabolic Diseases.

Author information

1
Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, ON, Canada.
2
Department of Medicine, McMaster University, 1280 Main Street West, Hamilton, ON, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, 1280 Main Street West, Hamilton, ON, Canada. Electronic address: gsteinberg@mcmaster.ca.

Abstract

The AMP-activated protein kinase (AMPK) is a central regulator of multiple metabolic pathways and may have therapeutic importance for treating obesity, insulin resistance, type 2 diabetes (T2D), non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease (CVD). Given the ubiquitous expression of AMPK, it has been a challenge to evaluate which tissue types may be most beneficially poised for mediating the positive metabolic effects of AMPK-centered treatments. In this review we evaluate the metabolic phenotypes of transgenic mouse models in which AMPK expression and function have been manipulated, and the impact this has on controlling lipid metabolism, glucose homeostasis, and inflammation. This information may be useful for guiding the development of AMPK-targeted therapeutics to treat chronic metabolic diseases.

KEYWORDS:

NAFLD; NASH; adipose tissue; atherosclerosis; beige adipose tissue; brown adipose tissue; macrophages

Comment in

PMID:
28647324
DOI:
10.1016/j.tem.2017.05.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center